AndroGel Reverse Payment Suits Thrown Out

By Brendan Pierson

Law360, New York (February 23, 2010, 4:05 PM ET) -- A federal judge has thrown out suits by the Federal Trade Commission and private plaintiffs challenging patent settlements in which Solvay Pharmaceuticals Inc. paid generic-drug makers not to compete with its testosterone supplement AndroGel, joining other federal courts in upholding drug companies' right to make so-called reverse payment deals.

Judge Thomas W. Thrash of the U.S. District Court for the Northern District of Georgia ruled Tuesday the settlements were legal because they didn't extend Solvay's monopoly on AndroGel past the expiration of its patent on the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles